Background and Objective: According to the guidelines for diabetic care in Gotland, SGLT2-inhibitors and GLP-1-analogues are recommended as an add-on treatment for when metformin in monotherapy, exercise and diet recommendations are insufficient. The aim of this study was to gain a better understanding of the effect of SGLT2-inhibitors and GLP-1-analogues on HbA1c and weight changes in patients with type II diabetes in Gotland. In addition, an overview of respective antidiabetics prescriptions in patients from Wisby Söder Health Center was performed. Study design: A retrospective quantitative study with data from three health centers in Gotland. The study population included diabetes type II patients who were prescribed SGLT-inhibitors or GLP-1-analogues during the period 2018-06-30 to 2020-06-30. This study collected data from Wisby Söder Health Center which further was used for the compilation of data from two previous student projects performed at Visby Norr and Visborg Health Center. Results were presented descriptively, a linear regression-analysis and ANOVA-test was performed. Setting: The study was conducted at Visborg, Visby Norr and Wisby Söder Health Center. Main outcome measures: The primary outcome was the change in HbA1c and weight changes as a secondary outcome. Another objective was to identify the proportion of patients with insufficient treatment defined as <10 mmol/mol HbA1c-reduction with either drug. Results: In total, 134 patients with SGLT2-inhibitors and 182 patients with GLP-1-analogues were included. The mean HbA1c-reduction for SGLT2-inhibitor was 11 mmol/mol (±13,5 95% KI 6,9-11,2) and for GLP-1-analogues 12 mmol/mol (±14,5 95% KI: 6,9-11,1). For each drug the mean weight reduction was 3 kg (±3). There was no correlation between age and HbA1c-changes. Conclusion: In conclusion, similar HbA1c and weight reductions were achieved with the respective drugs as in previous studies. However only about 50% of the population achieved a HbA1c-decrease with >10 mmol/mol. This indicates that further measures might need to be taken to optimize diabetes care in Gotland.
| Identifer | oai:union.ndltd.org:UPSALLA1/oai:DiVA.org:uu-483807 |
| Date | January 2022 |
| Creators | Salinas Achusim, Stephanie |
| Publisher | Uppsala universitet, Institutionen för farmaci |
| Source Sets | DiVA Archive at Upsalla University |
| Language | Swedish |
| Detected Language | English |
| Type | Student thesis, info:eu-repo/semantics/bachelorThesis, text |
| Format | application/pdf |
| Rights | info:eu-repo/semantics/openAccess |
Page generated in 0.0146 seconds